Breast cancer patients resistant to endocrine therapy show decreased number of cytotoxic supressor cells and enhanced production of neoangiogenetic and immunosupressive factors
Endocrine therapy is an essential modality in patients with hormone receptor positive breast cancer. Even with high therapeutic efficacy of first-line hormonal treatment, most patients with metastatic breast cancer will develop resistance.